[三季报]健康元(600380):健康元药业集团股份有限公司2024年第三季度报告（英文版）
|
时间：2024年10月24日 17:51:09 中财网 |
|
原标题: 健康元: 健康元药业集团股份有限公司2024年第三季度报告（英文版）
Stock Code: 600380 Stock Short Name: 健康元
Joincare Pharmaceutical Group Industry Co., Ltd.
2024 Third Quarterly Report
The Board of Directors and all Directors of the Company hereby warrant that there are no false representations, misleading statements or material omissions contained in this announcement and accept legal responsibility for the truthfulness, accuracy and completeness of the contents hereof.
IMPORTANT NOTICE:
? The Board of Directors, the Board of Supervisors and Directors, Supervisors and senior management
of the Company hereby warrant the truthfulness, accuracy and completeness of the contents of this quarterly report, and that there are no false representations, misleading statements or material omissions contained herein, and severally and jointly accept legal responsibility. ? The person-in-charge of the Company, the person-in-charge of accounting work and the person-in-charge of the accounting department (the head of the accounting department) hereby warrant the truthfulness, accuracy and completeness of the financial information contained in this quarterly report.
? Whether the third quarterly financial statements have been audited. □Yes √No
I. MAJOR FINANCIAL DATA
(I) Major Accounting Data and Financial Indicators
Unit: Yuan Currency: RMB
| Item | For the Reporting
Period | YoY change (%) | From the
beginning of the
year to the end of
the Reporting
Period | YoY change (%) | | Revenues | 3,664,194,805.57 | -6.80 | 11,898,828,905.02 | -5.95 | | Net profit attributable to
Shareholders of the listed
company | 335,135,597.05 | 24.95 | 1,111,560,063.92 | 2.58 | | Net profit attributable to
Shareholders of the listed
company after deduction of
extraordinary gain and loss | 311,474,846.35 | 16.45 | 1,073,381,416.07 | 2.30 | | Net cash flow from operating
activities | N/A | N/A | 2,613,605,501.06 | 6.25 | | Basic earnings per share
(RMB/share) | 0.18 | 26.01 | 0.59 | 4.63 | | Diluted earnings per share
(RMB/share) | 0.18 | 26.79 | 0.59 | 4.97 | | Weighted average return on
net assets (%) | 2.32 | Increased by 0.39
percentage points | 7.82 | Decreased by 0.40
percentage points | | | As at the end of the
Reporting Period | As at the end of the previous year | Change in the
ending amount of
the Reporting
Period to that of
the previous year
(%) | | | Total assets | 36,172,500,281.87 | 36,358,126,258.82 | -0.51 | | | Net assets attributable to
Shareholders of the listed
company | 14,487,774,610.56 | 13,755,901,924.06 | 5.32 | |
Notes: 1. The “Reporting Period” represents the 3-month period from the beginning to the end of this
quarter, the same below.
2. From January to September 2024, the Company’s Chemical pharmaceuticals achieved revenues of RMB5,879 million, representing a year-on-year decrease of 10.55%. Among them, revenues from gonadotropic hormones products reached RMB2,308 million, representing a year-on-year increase of 5.46%; revenues from gastroenterology products reached RMB1,854 million, representing a year-on-year
decrease of 18.66%; revenues from respiratory formulation products reached RMB799 million, representing a year-on-year decrease of 28.18%; revenues from psychiatry products reached RMB443 million, representing a year-on-year increase of 3.11%; and revenues from anti-infective products reached
RMB322 million, representing a year-on-year decrease of 19.46%. Revenues from APIs and intermediates
amounted to RMB3,857 million, representing a year-on-year decrease of 2.83%. Revenues from traditional Chinese medicine (TCM) formulations were RMB1,084 million, representing a year-on-year decrease of 16.06%. Revenues from diagnostic reagents and equipment were RMB566 million, representing a year-on-year increase of 21.03%. Revenues from health care products amounted to RMB262 million, representing a year-on-year increase of 97.67%, while revenues from biological products reached RMB131 million, representing a year-on-year increase of 15.98%. 3. From January to September 2024, the Company realized net profit attributable to shareholders of the parent of RMB1,112 million, of which Joincare (excluding Livzon Group and Livzon MAB) realized net profit attributable to shareholders of the parent of approximately RMB479 million, representing a YoY
decrease of approximately 21.65%, and the impact of Livzon MAB on the net profit attributable to (II) Items and Amounts of Extraordinary Gains and Losses
√Applicable □N/A
Unit: Yuan Currency: RMB
| Item | For the
Reporting Period | From the beginning of the
year to the end of the
Reporting Period | | Gains and losses on disposal of non-current assets (including the
reversal of previously recognized asset impairment provisions) | -303,991.87 | -380,432.23 | | Government grants recognized in profit or loss for the current
period (excluding government grants that are closely related to
the business of the Company and are provided in fixed amount
or quantity continuously according to the applicable polices and
standards of the country). | 44,861,228.31 | 97,182,195.46 | | Excluding effective hedging activities related to the company's
ordinary operating business, this refers to gains and losses
arising from changes in the fair value of financial assets and
financial liabilities held by non-financial enterprises, as well as
gains and losses from the disposal of financial assets and
financial liabilities. | 15,453,330.81 | -1,320,002.12 | | Other non-operating income and expenses excluding the above
items | -8,178,945.07 | -13,068,229.51 | | Less: Effect of income tax | 6,413,048.49 | 12,226,800.99 | | Effect of minority equity (after tax) | 21,757,822.99 | 32,008,082.76 | | Total | 23,660,750.70 | 38,178,647.85 |
For the items not listed in the “Explanatory Announcement No.1 for Public Company Information Disclosures-Extraordinary Gains or Losses” that the company identifies as non-recurring gains and losses,
especially those with significant amounts, as well as the extraordinary gain or loss items as illustrated in
the “Explanatory Announcement No.1 for Public Company Information Disclosures-Extraordinary Gains or Losses” which has been defined as its recurring gain or loss items, the reasons for such classification
should be explained.
□Applicable √N/A
(III) Changes in Major Accounting Data and Financial Indicators and Reasons Thereof □Applicable √N/A
(IV) Material Changes in Other Items in Financial Statements and Financial Indicators and Reasons Thereof
Unit: Yuan Currency: RMB
| Balance Sheet | 30 September
2024 | 31 December
2023 | Change in
proportion
（%） | Main Reason | | Other receivables | 85,854,197.50 | 46,010,624.61 | 86.60 | Mainly due to the stock
options exercised by
employees of the subsidiary
Livzon Group this period
have not yet received the
corresponding payment. | | Non-current assets due
within one year | 650,845,317.12 | 406,376,425.44 | 60.16 | Mainly due to an increase in
time deposits maturing
within one year. | | Other current assets | 294,526,056.46 | 77,402,185.01 | 280.51 | Mainly due to new short-
term cash management
activities. | | Other non-current
financial assets | 1,399,815,097.39 | 957,224,255.77 | 46.24 | Mainly due to new cash
management activities. | | Financial liabilities held
for trading | 267,731.76 | 86,817.12 | 208.39 | Mainly due to changes in the
fair value of forward foreign
exchange contracts. | | Contract liabilities | 98,823,153.11 | 159,082,637.65 | -37.88 | Mainly due to the
recognition of revenue from
contract advances that met
the criteria for revenue
recognition during this
period. | | Taxes payable | 271,059,346.85 | 410,202,854.09 | -33.92 | Mainly due to a decrease in
corporate income tax
payable this period. | | Non-current liabilities
due within one year | 1,930,684,639.47 | 718,564,144.31 | 168.69 | Mainly due to the transfer of
long-term loans maturing
within one year. | | Other current liabilities | 12,832,993.44 | 51,087,001.83 | -74.88 | Mainly due to a decrease in
estimated refund liabilities. | | Long-term loans | 1,372,606,325.72 | 3,122,273,278.99 | -56.04 | Mainly due to the
reclassification of long-term
loans maturing within one
year to current liabilities. | | Other comprehensive
income | -65,054,363.34 | -12,246,131.22 | N/A | Mainly due to changes in the
fair value of other equity
instruments and fluctuations
in exchange rates, resulting
in variations in foreign
currency translation
adjustments. | | Statement of Income | January to
September 2024 | January to
September 2023 | Change in
proportion
（%） | Main Reason | | Financial expenses | -105,969,421.63 | -314,423,140.18 | N/A | Mainly due to a decrease in
interest income from
deposits and fluctuations in
foreign exchange gains and
losses. | | Gains from changes in
fair value | -5,736,443.62 | -46,003,628.22 | N/A | Mainly due to fluctuations in
the market value of held
securities investments. | | Losses of credit
impairment | -797,210.83 | -17,737,505.85 | N/A | Mainly due to a decrease in
long-aged accounts
receivable, leading to a
corresponding reduction in
expected credit impairment
losses. | | Impairment loss of
assets | -370,399.04 | -200,478.63 | N/A | Mainly due to an increase in
losses from the disposal of
fixed assets. | | Other comprehensive
income, net of tax | -86,688,069.37 | -22,658,520.87 | N/A | Mainly due to changes in the
fair value of other equity
instrument investments and
fluctuations in exchange | | | | | | rates, resulting in variations
in foreign currency
translation adjustments. | | Cash Flow Statement | January to
September 2024 | January to
September 2023 | Change in
proportion
（%） | Main Reason | | Net cash flows from
investing activities | -1,183,961,052.92 | -675,752,976.46 | N/A | Mainly due to a higher
amount of investment
payments made during the
current period. |
II. SHAREHOLDERS
(I) Total Number of Holders of Ordinary Shares and Number of Holders of Preferred Shares with Restored
Voting Rights and Shareholdings of Top 10 Shareholders
Unit: shares
| Total number of holders of ordinary
shares as of the end of the Reporting
Period | 76,823 | Total number of holders of preferred
shares with restored voting rights as of the
end of the Reporting Period (if any) | 0 | | | | | Shareholdings of the top 10 shareholders
（excluding shares lent through refinancing business） | | | | | | | | Name of shareholder | Nature of
shareholder | Number of
shares held | Percentage
(%) | Number of
shares held
with selling
restrictions | Pledge, mark or lock-up | | | | | | | | Share
status | Number | | Shenzhen Baiyeyuan Investment Co., Ltd.
(深圳市百业源投资有限公司) | Domestic non-
state-owned
legal person | 895,653,653 | 47.79 | 0 | Pledge | 55,679,725 | | Hong Kong Securities Clearing Company
Limited | Unknown | 97,098,746 | 5.18 | 0 | Unknown | | | Might Seasons Limited | Foreign legal
person | 35,929,699 | 1.92 | 0 | Unknown | | | Agriculture Bank of China Limited-CSI
500 Exchange Traded Index Securities
Invest Fund | Unknown | 20,006,912 | 1.07 | 0 | Unknown | | | Perseverance Asset Management L.L.P–
Gaoyi Xiaofeng No. 2 Zhixin Fund | Unknown | 14,364,600 | 0.77 | 0 | Unknown | | | China Foreign Economy and Trade Trust
Co., Ltd.–Foreign Trust–Gaoyi Xiaofeng
Hongyuan Collection Fund Trust Plan | Unknown | 13,130,100 | 0.70 | 0 | Unknown | | | Rui Life Insurance Co., Ltd. - Own fund | Unknown | 12,729,218 | 0.68 | 0 | Unknown | | | Abu Dhabi Investment Authority | Foreign legal
person | 12,502,378 | 0.67 | 0 | Unknown | | | CPIC Fund -China Pacific Life Insurance
Co., Ltd. -with-profit insurance-CPIC
Fund China Pacific Life Equity Relative
Income (Guaranteed Dividend) single
assets management plan | Unknown | 10,170,000 | 0.54 | 0 | Unknown | | | Bank of Shanghai Co., Ltd.－Yinhua CSI
Innovative Drug Industry Trading Open-
end Index Securities Investment Fund | Unknown | 9,836,796 | 0.52 | 0 | Unknown | | | Shareholdings of the top 10 shareholders without selling restrictions
（excluding shares lent through refinancing business） | | | | | | | | Name of shareholder | Number of tradable shares
held without selling
restrictions | Class and number of shares | | | | | | | | Class of shares | Number | | | |
| Shenzhen Baiyeyuan Investment Co., Ltd. (深圳市百业源
投资有限公司) | 895,653,653 | Ordinary shares
denominated in Renminbi | 895,653,653 | | Hong Kong Securities Clearing Company Limited | 97,098,746 | Ordinary shares
denominated in Renminbi | 97,098,746 | | Might Seasons Limited | 35,929,699 | Ordinary shares
denominated in Renminbi | 35,929,699 | | Agriculture Bank of China Limited-CSI 500 Exchange
Traded Index Securities Invest Fund | 20,006,912 | Ordinary shares
denominated in Renminbi | 20,006,912 | | Perseverance Asset Management L.L.P–Gaoyi Xiaofeng
No. 2 Zhixin Fund | 14,364,600 | Ordinary shares
denominated in Renminbi | 14,364,600 | | China Foreign Economy and Trade Trust Co., Ltd.–Foreign
Trust–Gaoyi Xiaofeng Hongyuan Collection Fund Trust
Plan | 13,130,100 | Ordinary shares
denominated in Renminbi | 13,130,100 | | Rui Life Insurance Co., Ltd. - Own fund | 12,729,218 | Ordinary shares
denominated in Renminbi | 12,729,218 | | Abu Dhabi Investment Authority | 12,502,378 | Ordinary shares
denominated in Renminbi | 12,502,378 | | CPIC Fund -China Pacific Life Insurance Co., Ltd. -with-
profit insurance-CPIC Fund China Pacific Life Equity
Relative Income (Guaranteed Dividend) single assets
management plan | 10,170,000 | Ordinary shares
denominated in Renminbi | 10,170,000 | | Bank of Shanghai Co., Ltd.－Yinhua CSI Innovative Drug
Industry Trading Open-end Index Securities Investment
Fund | 9,836,796 | Ordinary shares
denominated in Renminbi | 9,836,796 | | Description of connection or acting-in-concert relationship
of the above shareholders | There was no connection or acting-in-concert relationship between Shenzhen
Baiyeyuan Investment Co., Ltd., a controlling shareholder of the Company,
and other shareholders; whether there is connection or acting-in-concert
relationship among other shareholders is unknown. | | | | Description of the participation of the top 10 shareholders
and the top 10 shareholders without selling restrictions in
margin financing and securities lending and refinancing
business (if any) | N/A | | |
Participation of shareholders holding over 5%, the top 10 shareholders, and the top 10 shareholders
without selling restriction in securities lending transactions of refinancing business √Applicable □N/A
Unit: shares
| Participation of shareholders holding over 5%, the top 10 shareholders, and the top 10 shareholders without selling restriction in securities
lending transactions of refinancing business | | | | | | | | | | Name of shareholder
(Full name) | Number of shares held in
ordinary and credit accounts
at the beginning of the
Period | | Number of shares lent
through refinancing
business and not yet
returned at the beginning
of the Period | | Number of shares held in
ordinary and credit
accounts at the end of the
Period | | Number of shares lent
through refinancing
business and not yet
returned at the end of the
Period | | | | Total
number | Proportion
(%) | Total
number | Proportion
(%) | Total
number | Proportion
(%) | Total
number | Proportion
(%) | | Agriculture Bank of
China Limited-CSI 500
Exchange Traded Index
Securities Invest Fund | 5,055,774 | 0.27 | 1,509,200 | 0.08 | 20,006,912 | 1.07 | 0 | 0.00 | | Bank of Shanghai Co.,
Ltd.－Yinhua CSI
Innovative Drug
Industry Trading Open-
end Index Securities
Investment Fund | 8,458,496 | 0.45 | 10,000 | 0.001 | 9,836,796 | 0.52 | 0 | 0.00 |
Changes in the top 10 shareholders and the top 10 shareholders without selling restriction due to securities
lending/returning transactions of refinancing business compared to the previous period III. OTHER REMINDERS
Other important information regarding the Company’s operations during the Reporting Period to which
investors should be reminded to pay attention.
□Applicable √N/A
IV. QUARTERLY FINANCIAL STATEMENTS
(I) Audit Opinion
□Applicable √N/A
(II) Financial Statements
Consolidated Balance Sheet
30 September 2024
Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd. Unit: Yuan Currency: RMB Audit status: Unaudited
| Item | 30 September 2024 | 31 December 2023 | | Current assets: | | | | Monetary funds | 14,594,801,258.03 | 15,691,888,314.83 | | Financial assets held for trading | 77,343,625.25 | 82,899,154.24 | | Notes receivable | 1,840,201,163.60 | 1,941,200,568.00 | | Accounts receivable | 2,672,357,170.76 | 2,692,941,866.24 | | Receivables financing | | | | Prepayments | 306,162,056.96 | 280,102,860.94 | | Other receivables | 85,854,197.50 | 46,010,624.61 | | In which: Interests receivable | | | | Dividends receivable | | | | Inventories | 2,605,104,655.82 | 2,655,808,391.09 | | Contract assets | | | | Assets held-for-sale | | | | Non-current assets due within one year | 650,845,317.12 | 406,376,425.44 | | Other current assets | 294,526,056.46 | 77,402,185.01 | | Total current assets | 23,127,195,501.50 | 23,874,630,390.40 | | Non-current assets: | | | | Debt investment | | | | Other debt investment | | | | Long-term receivables | | | | Long-term equity investment | 1,467,317,916.58 | 1,411,036,353.95 | | Other equity instrument investments | 1,066,048,054.16 | 1,155,283,408.36 | | Other non-current financial assets | | | | Investment properties | 16,327,550.42 | 16,958,213.00 | | Fixed assets | 5,638,056,264.70 | 5,664,352,555.97 | | Construction in progress | 662,547,623.17 | 531,059,118.06 | | Productive biological assets | | | | Oil and gas assets | | | | Right-of-use assets | 28,190,760.95 | 36,233,067.49 | | Intangible assets | 731,856,861.97 | 683,337,333.73 | | Development expenditures | 461,930,852.53 | 483,494,487.17 | | Goodwill | 636,339,503.82 | 636,339,503.82 | | Long-term deferred expenses | 317,024,375.10 | 328,642,740.95 | | Deferred income tax assets | 619,849,919.58 | 579,534,830.15 | | Other non-current assets | 1,399,815,097.39 | 957,224,255.77 | | Total non-current assets | 13,045,304,780.37 | 12,483,495,868.42 | | Total assets | 36,172,500,281.87 | 36,358,126,258.82 | | Current liabilities: | | | | Short-term loans | 2,050,000,000.00 | 2,076,159,347.22 | | Financial liabilities held for trading | 267,731.76 | 86,817.12 | | Notes payable | 1,433,953,960.81 | 1,469,148,287.38 | | Accounts payable | 832,051,361.15 | 894,286,243.28 | | Receipts in advance | | | | Contract liabilities | 98,823,153.11 | 159,082,637.65 | | Employee benefits payable | 382,925,497.74 | 399,466,473.91 | | Taxes payable | 271,059,346.85 | 410,202,854.09 | | Other payables | 3,553,679,167.04 | 3,682,604,038.73 | | In which: Interests payable | | | | Dividends payable | 10,022,086.38 | 12,478,280.13 | | Liabilities held-for-sale | | | | Non-current liabilities due within one year | 1,930,684,639.47 | 718,564,144.31 | | Other current liabilities | 12,832,993.44 | 51,087,001.83 | | Total current liabilities | 10,566,277,851.37 | 9,860,687,845.52 | | Non-current liabilities: | | | | Long-term loans | 1,372,606,325.72 | 3,122,273,278.99 | | Bonds payable | | | | Lease liabilities | 12,031,618.67 | 15,422,948.41 | | Long-term payables | | | | Long-term payroll payable | | | | Estimated liabilities | | | | Deferred income | 334,243,550.30 | 370,179,550.82 | | Deferred income tax liabilities | 252,362,201.09 | 260,032,144.44 | | Other non-current liabilities | 90,000,000.00 | 90,000,000.00 | | Total non-current liabilities | 2,061,243,695.78 | 3,857,907,922.66 | | Total liabilities | 12,627,521,547.15 | 13,718,595,768.18 | | Owner's equity (or shareholder's equity): | | | | Paid-in capital | 1,874,200,420.00 | 1,865,523,807.00 | | Other equity instruments | | | | In which: Preferred shares | | | | Perpetual debts | | | | Capital reserve | 1,592,054,957.78 | 1,601,720,087.71 | | Less: Treasury shares | | | | Other comprehensive income | -65,054,363.34 | -12,246,131.22 | | Special reserve | | | | Surplus reserve | 859,046,203.77 | 859,046,203.77 | | Undistributed profits | 10,227,527,392.35 | 9,441,857,956.80 | | Total owner's equity (or shareholder's equity)
attributable to the parent | 14,487,774,610.56 | 13,755,901,924.06 | | Minority shareholder's equity | 9,057,204,124.16 | 8,883,628,566.58 | | Total owner's equity (or shareholder's equity) | 23,544,978,734.72 | 22,639,530,490.64 | | Total liabilities and owner's equity (or
shareholder's equity) | 36,172,500,281.87 | 36,358,126,258.82 |
Person-in-charge of the Person-in-charge of the Person-in-charge of the Company: Zhu Baoguo Company's accounting work: accounting department: Qiu Qingfeng Guo Chenlu
Consolidated Income Statement
From January to September, 2024
Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd. Unit: Yuan Currency: RMB Audit status: Unaudited
| Item | First three quarters
(January to September)
for 2024 | First three quarters
(January to September)
for 2023 | | I. Total revenues | 11,898,828,905.02 | 12,651,257,386.44 | | In which: Operating revenues | 11,898,828,905.02 | 12,651,257,386.44 | | II. Total operating costs | 9,121,682,123.61 | 9,992,088,727.85 | | In which: Operating costs | 4,393,919,087.41 | 4,836,588,741.76 | | Operating tax and surcharges | 137,567,242.03 | 150,278,107.37 | | Selling expenses | 2,951,059,287.90 | 3,428,038,993.64 | | Administrative expenses | 708,729,617.84 | 680,009,158.86 | | R&D expenses | 1,036,376,310.06 | 1,211,596,866.40 | | Financial expenses | -105,969,421.63 | -314,423,140.18 | | In which: Interest expenses | 94,972,898.62 | 106,424,878.84 | | Interest income | 245,985,558.70 | 373,189,603.11 | | Add: Other income | 124,184,202.58 | 150,725,832.49 | | Income from investments (loss is
indicated by“-”) | 51,650,239.89 | 58,569,845.80 | | In which: Income from investments
in associates and joint ventures | 34,370,020.06 | 57,873,393.21 | | Gains from derecognition of financial
assets at amortized cost | | | | Gains from net exposure hedges (loss
is indicated by“-”) | | | | Gains from changes in fair values
(loss is indicated by“-”) | -5,736,443.62 | -46,003,628.22 | | Losses of credit impairment (loss is
indicated by“-”) | -797,210.83 | -17,737,505.85 | | Assets impairment loss (loss is
indicated by“-”) | -113,694,072.70 | -108,440,945.45 | | Gains from disposal of assets (loss is
indicated by“-”) | -370,399.04 | -200,478.63 | | III. Operating profit (loss is indicated
by“-”) | 2,832,383,097.69 | 2,696,081,778.73 | | Add: Non-operating income | 6,920,279.40 | 6,302,873.99 | | Less: Non-operating expenses | 19,988,508.91 | 23,765,998.31 | | IV. Total profit (loss is indicated by“-”) | 2,819,314,868.18 | 2,678,618,654.41 | | Less: Income tax expenses | 385,618,343.11 | 433,823,342.57 | | V. Net profit (loss is indicated by“-”) | 2,433,696,525.07 | 2,244,795,311.84 | | (I) Classified by business continuity | | | | 1. Net profit from ongoing operation
(loss is indicated by“-”) | 2,433,696,525.07 | 2,244,795,311.84 | | 2. Net profit from discontinuing
operation (loss is indicated by“-”) | | | | (II) Classified by ownership | | | | 1.Net profit attributable to shareholders
of the parent (loss is indicated by“-”) | 1,111,560,063.92 | 1,083,649,154.75 | | 2.Profit and loss of minority
shareholders (loss is indicated by“-”) | 1,322,136,461.15 | 1,161,146,157.09 | | VI. Other comprehensive income, net of
tax | -86,688,069.37 | -22,658,520.87 | | (I) Other comprehensive income
attributable to owners of the parent, net
of tax | -59,369,859.17 | 1,005,760.40 | | 1. Other comprehensive income that
cannot be reclassified into profit or loss | -58,031,748.84 | -31,488,647.75 | | (1) Changes from remeasurement of
defined benefit plans | | | | (2) Other comprehensive income that
cannot be reclassified into profit or loss
under the equity method | | | | (3) Changes in fair value of
investments in other equity instruments | -58,031,748.84 | -31,488,647.75 | | (4) Changes in fair value of the
enterprise's own credit risks | | | | 2. Other comprehensive income that
will be reclassified into profit or loss | -1,338,110.33 | 32,494,408.15 | | (1) Other comprehensive income that
can be reclassified into profit or loss under
the equity method | -174,001.08 | 164,225.81 | | (2) Changes in fair value of other
debt investments | | | | (3) Amount of financial assets
reclassified into other comprehensive
income | | | | (4) Provision for credit impairment of
other debt investments | | | | (5) Reserve for cash flow hedges | | | | (6) Exchange translation differences
on financial statements denominated in
foreign currencies | -1,164,109.25 | 32,330,182.33 | | (7) Others | | | | (II) Other comprehensive income
attributable to minority shareholders, net
of tax | -27,318,210.20 | -23,664,281.27 | | VII. Total comprehensive income | 2,347,008,455.70 | 2,222,136,790.97 | | (I) Total comprehensive income
attributable to owners of the parent
company | 1,052,190,204.75 | 1,084,654,915.15 | | (II) Total comprehensive income
attributable to minority shareholders | 1,294,818,250.95 | 1,137,481,875.82 | | Ⅷ. Earnings per share | | | | (I) Basic earnings per share (RMB/share) | 0.5945 | 0.5682 | | (II) Diluted earnings per share
(RMB/share) | 0.5944 | 0.5663 |
（未完）
|
|
